Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Sight Sciences Wins FDA Nod For OMNI Ultra Glaucoma Surgery System; On Track For Q4 Launch

5 August 2026 · By · Wire by Fusion42

Published

5 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

Sight Sciences has received FDA approval for its OMNI Ultra Glaucoma Surgery System and plans to launch it in Q4. This marks a regulatory milestone enabling market entry for this new surgical technology.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

United States medtech founders should prioritise preparing for market entry as new FDA clearance unlocks commercial opportunities in glaucoma surgery. Competitors and suppliers in eye surgery tech should expect heightened activity this quarter.

◆ Coverage

1 source · 5 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalglaucoma-surgerymedtechus-market-entry